Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-16
2007-10-16
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S122000, C544S323000, C544S324000
Reexamination Certificate
active
11125614
ABSTRACT:
The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.
REFERENCES:
patent: 4983608 (1991-01-01), Effland et al.
patent: 5043317 (1991-08-01), Chapman et al.
patent: 5935966 (1999-08-01), Suto et al.
patent: 5958935 (1999-09-01), Davis et al.
patent: 6080858 (2000-06-01), Schumacher
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6716831 (2004-04-01), Breault et al.
patent: 2004/0171630 (2004-09-01), Kim et al.
patent: 0 002 341 (1979-06-01), None
patent: 0 379 806 (1996-04-01), None
patent: 0 945 443 (1999-09-01), None
patent: 0 945 443 (1999-09-01), None
patent: 1 040 831 (2000-04-01), None
patent: WO94/26733 (1994-11-01), None
patent: WO95/33750 (1995-12-01), None
patent: WO96/05177 (1996-02-01), None
patent: WO97/19065 (1997-05-01), None
patent: WO98/18782 (1998-05-01), None
patent: WO99/31073 (1999-06-01), None
patent: WO99/41253 (1999-08-01), None
patent: WO99/50250 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/27825 (2000-05-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/43373 (2000-07-01), None
patent: WO 00/53595 (2000-09-01), None
patent: WO 00/59892 (2000-10-01), None
patent: WO 00/63204 (2000-10-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/00213 (2001-01-01), None
patent: WO 01/22938 (2001-04-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/40218 (2001-06-01), None
Amemiya et al., “Synthesis and α-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues”, Journal of Medicinal Chemistry, 35:750-755 (1992).
Amemiya et al., “Dehydrogenation of imidazolines to imidazoles with palladium-carbon”, Synthetic Communications, 20(16): 2483-2490 (1990).
Arutyunyan et al., “Reaction of uracils with Phosphoric acid amides”, Abstract IZV. AKAD. NAUK SSR, SER. KHIM (4):904-909 (1970).
Bairoch,The Enzyme Database, Nucleic Acids Research, 28 (1): 304-305 (2000).
Braunwalder, et al.,A solid-phase assay for the determination of protein tyrosine kinase activity of c-src using scintillating microtitration plates, Analytical Biochemistry 234 (1): 23-26 (1996).
Brunet et al.,Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor, Cell 96: 857-868 (1999).
Buchdunger et al.,Inhibition of the Abl protein -tyrosine kinasein vitro and in vivoby a 2-Phenylaminopyrimidine Derivative, Cancer Research, 56, 100-104 (1996).
Cleaveland et al.,A microtiter-based assay for the detection of protein tyrosine kinase activity, Anal Biochem 190 (2): 249-253 (1990).
Czarnik,Encoding methods for combinatorial chemistry, Current Opinions Chemical Bio., 1: 60-66 (1997).
El-Kerdawy et al., “Synthesis of certain esters of pteroyl glutamic acid analogues structurally related to antimetabolite anticancer compounds”, Journal of Pharmaceutical Sciences or the United Arab Republic, 9:1-6 (1968).
Fieser et al.,Fieser&Fieser's Reagents for Organic Synthesis, John Wiley & Sons (1994).
Garcia-Bustos et al.,PIK1, an essential phosphatidylinositol 4-Kinase associated with the yeast nucleus, The EMBO Journal, 13 (10): 2352-2361 (1994).
Gish et al.,Bacterial expression, purification and preliminary kinetic description of the kinase domain of v-fps, Protein Engineering, 8 (6): 609-614 (1995).
Ghosh et al., “2,4-Bis (p-chloroanillino) pyrimidine, an uncoupler of oxidative phosphorylation”, Abstract, FEBS Lett., 4(3):157-159 (1969).
Ghosh et al., “2,4-Bis (arylamino)-6-methylpyrimidines as antimicrobial agents”, Abstract, J. Indian Chem. Soc., 48(5):512-513 (1981).
Greene,Protective Groups in Organic Synthesis, 2ndEd., John Wiley & Sons (1991).
Grigor'eva et al., Catalytic activity of complexes of copper (II) with carboxyphenylaminopyrimidines antiinflammatory drugs in model reactions of oxidase and catalase type, Chemical Abstracts, 89:36533 (1978).
Hanks et al.,The eukaryotic protein kinase superfamily: kinase(catalytic)domain structure and classificationFASEB Journal, 9: 576-596 (1995).
Hardie,The Protein Kinase Facts Book, I&II, Academic Press, San Diego, CA (1995).
Hiles et al.,Phosphatidylinositol 3-Kinase: Structure and Expression of the 110 kd Catalytic Subunit, Cell, 70: 419-429 (1992).
Hoffmann et al.,The PROSITE database, its status in 1999, Nucleic Acids, Res. 27 (1): 215-219 (1999).
Kaga, Shuji, et al.,Activation of p21-CDC42/RAC-activated kinases by CD28 signaling: p21-activated kinase(PAK)and MEK kinase 1(MEKK1)may mediate the interplay between CD3 and CD28 signals, Journal of Immunology 160: 4182-4189 (1998).
Karp et al., “Synthesis and antiinflammatory properties of o-carboxyphenylaminopyrimidines”, Abstract, KHIM.—Farm. Zh. 17(11):1304-1307 (1983).
Kirk,Facile Synthesis of 2 Substituted Imidazoles, J. Org. Chem 43 (22), 4381-4383 (1978).
Knighton et al.,Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein KinaseScience, 253: 407-414 (1991).
Koguro et al., “Novel synthesis of 5-substituted tetrazoles from nitriles”, Synthesis, 910-914 (1997).
Kolb et al.,Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence, Drug Discovery Today, 3 (7):333-342, (1998).
Kume et al., “Orally active cephalosporins. II. Synthesis and structure-activity relationships of new 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-caphalosporins with 1,2,3-triazole in C-3 side chain”, Journal of Antibiotics, 46(1):177-192 (1993).
Kunz et al,Target of Rapamycin in yeast, TOR2 is an essential phosphatidylinositol kinase homolog required for G, progression, Cell, 73: 585-596 (1993).
Larock,Comprehensive Organic Transformations, VCH Publishers (1989).
Lehr et al.,Production, purification and characterization of non-myristylated human T-cell protein tyrosine kinase in a baculovirus expression system, Gene 169; 275-279 (1996).
Liu et al.,Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation, Current Biology, 7 (11): 817-826 (1997).
Nagata et al., “Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor”, Journal of Medicinal Chemistry, 37:3956-3968 (1994).
Obrecht et al.,Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecula- Weight Compound Libraries, Pergamon-Elsevier Science Limited(1998).
Olayioye et al.,ErB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner, Molecular & Cellular Biology, 18 (9): 5042-5051 (1998).
Paquette,Encyclopedia Of Reagents For Organic Synthesis, John Wiley & Sons (1995).
Pozdnev, “Activation of carboxylic acids by pyrocarbonates. Application of di-tert-butyl pyrocarbonate as condensing reagent in the synthesis of amides of protected amino acids and peptides”, Tetrahedron Letters, 36(39):7115-7118 (1995).
Satterthwaite,Independent and opposing roles for Btk and Lyn in B cell and myeloid signaling pathways, J. of Exp. Med. 188 (5): 833-844 (1998).
Seethala et al.,A fluorescence polarization competition immunoassay for tyrosine kinases, Anal. Biochem., 255 (2): 257-262 (1998).
Stephan et al.,FcεR1-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells(RBL-2H3) , Journal of Biological Chemistry, 267 (8): 5434-5441, (1992).
Tepe et al., “Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain”, Journal of Medicinal Chemistry, 39:2188-2196 (1996).
Wu et al.,Measurement of Cdk4 kinase
Armistead David M.
Bemis Jean E
DiPietro Lucian V
Geuns-Meyer Stephanie D.
Habgood Gregory J.
Amgen Inc.
Bulock Joseph W.
Rao Deepak
LandOfFree
Kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834581